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Determining the impact of antiretroviral therapy on virus evolution could advance the development of improved therapeutics/vaccines against
HIV. Toward this goal, we analyzed virus burden, quasispecies complexity, and T cell responses in SIV/DeltaB670-infected rhesus macaques±
treatment for 7 months with PMPA (2–30 weeks postinfection). Treatment divided the animals into two groups: poor responders (a reduction of≤
1 log) and responders (≥2 log reduction) in virus burden. Virus evolution in poor responders and untreated controls was characterized by expression
of a complex quasispecies that evolved as the disease progressed. This included the universal loss of a viral genotype selected against by in vitro
passage in monkey cells and selected for by propagation in human cells. In contrast, a good response to PMPAwas characterized by infection with a
less complex quasispecies that evolved more slowly. Interestingly, in 2 of the best responders, the human-preferred genotype persisted until the
study was discontinued (89 weeks p.i.). Neither virus burden nor the magnitude of the T cell response at 2 weeks postinfection predicted PMPA
responsiveness. However, responders expressed a less complex quasispecies than nonresponders prior to treatment. These data suggest a role for
intrinsic host factors in treatment responsiveness, and lend support for therapeutic vaccination as an adjunct to effective therapy.
© 2006 Elsevier Inc. All rights reserved.Keywords: Antiretroviral therapy (ART); (R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA); SIV; Heteroduplex tracking analysis (HTA); Envelope; Diversity;
EvolutionIntroduction
Treatment of HIV-infected individuals with one or more
drugs that interfere with the viral life cycle has provided a
significant therapeutic benefit by reducing the clinical symptoms
and prolonging the life of infected individuals (Detels et al.,
1998; Egger et al., 1997; Palella et al., 1998). These therapies are
not perfect, however, because they do not eradicate the virus
(Chun et al., 1997), and treatment fatigue and/or the emergence
of drug resistant strains eventually occur (Bagnarelli et al., 1995;
Condra et al., 1995) which frequently heralds an increase in virus⁎ Corresponding author. Fax: +1 412 967 6568.
E-mail address: mcorb@pitt.edu (M. Murphey-Corb).
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doi:10.1016/j.virol.2006.06.025burden and a return of symptoms. Additionally, not all people
respond well to therapy (Grabar et al., 2000; Kaufmann et al.,
1998). What is needed to offset these shortfalls is the
development of strategies that, when given in combination,
augment the effects of therapy, and allow continued control once
treatment is terminated. A better understanding of the impact of
drug treatment on the virus and how host factors influence this
process is essential to these efforts. In infected humans, such
studies are confounded by the extent of HIV genetic variation
and sorting out the multiple selective pressures that drive viral
evolution. The exhaustive genetic analysis of HIV strains
isolated across the globe and longitudinally over time in
numerous infected individuals has provided some insight into
this process. Foremost in these events is the evolution associated
with the ongoing adaptation of the virus to replication in the host
Table 1
Study outcome of SIV/DeltaB670-infected untreated and PMPA-treated a
animals
Group Animal
number
Survival
(days)
Mamu
haplotype
Cause of death
Untreated
control
M11599 101 A*08.B*03 CMV pneumonia
M10699 474 A*08 SIV giant cells in
lung
M10399 360 A*02 Meningitis
M4599 365 B*01. B*03 PCP pneumonia,
cryptosporidium
PMPA, poor
responder
M10899 240 B*01 CMV,
lymphosarcoma
M9699 589 b A*01, A*02 Euthanasia
M11399 394 Unknownc Lymphosarcoma,
meningitis
M12499 664 b A*01, A*02 Euthanasia
PMPA,
responder
M10999 636 b Unknown c Euthanasia
M9099 662 b A*01 Euthanasia
M9799 660 b A*08,B*01,
B*03
Euthanasia
M13799 664 b A*01,B*01,
B*03
Euthanasia
a Daily PMPA treatment (20 mg/kg) initiated 14 days pi, continued 6 months
then withdrawn.
b Scheduled sacrifice.
c Haplotype was not Mamu; A*01, A*02, A*08, A*11, B*01, B*03, B*04,
B*17.
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selection of nascent genotypes capable of evading either B
(Albert et al., 1990; Montefiori et al., 1991) or T cell immunity
(Allen et al., 2005; Borrow et al., 1997; Goulder et al., 1997;
Price et al., 1997). Together, these forces play a collective role in
driving divergence and diversity in the virus population over
time (Lukashov et al., 1995; Shankarappa et al., 1999).
More recently, the selection of drug resistant strains as a
consequence of long term antiretroviral therapy has also
impacted HIV evolution. Drug resistant viruses, however, are
often poorly competitive with their drug sensitive counterparts
and are lost during the viral rebound that follows treatment
interruption (Devereux et al., 1999, 2001; Kijak et al., 2002).
Interestingly, the drug sensitive genotypes expressed during
rebound are often more closely related to viruses replicating
during early infection (ancestral strains) than the more recently
expressed drug resistant genotypes. This finding has promoted
the concept of organ and/or cellular reservoirs of latent virus
that provide a continual source of virus during chronic infection
(Chun et al., 2000; Zhang et al., 2000).
Similar evolutionary pressures exist in the SIV:macaque
model for AIDS as well. Evasion of T cell immunity via
selection of epitope escape mutants is well described in the
infected macaque (Chen et al., 2000; Evans et al., 1999;
O'Connor et al., 2004) as well as the emergence of drug resistant
strains during antiretroviral therapy (Van Rompay et al., 1996).
Adaptation to growth in different species most certainly occurs
as well. Many of the virus stocks used today that were originally
isolated from the Sooty Mangabey monkey, have been
extensively passaged in the rhesus macaque (Courgnaud et al.,
1998; Demma et al., 2005; Murphey-Corb et al., 1986; Staprans
et al., 1999; Trichel et al., 2002). SIV is also frequently
propagated in human cell lines for use in in vitro assays and the
preparation of virus stocks for in vivo studies. This recurrent
switching of primate hosts provides an ideal environment of
genetic instability for SIV that promotes a continuous state of
viral evolution independent of host immune selection. In this
report, we used this knowledge and a virus stock whose
passage history and genetics are known (Amedee et al., 1995)
to provide insight into lentiviral virus:host:drug interactions by
analyzing the virological response to monotherapy with the
nucleotide analog (R)-9-(2-phosphonomethoxypropyl) adenine
(PMPA).
Results
Study design
Virus burden, quasispecies evolution, and SIV-specific T cell
responses were evaluated in 12 SIV/DeltaB670-infected rhesus
macaques temporally treated with PMPA to identify factors
associated with the response to treatment and rebound after
treatment interruption. When compared to HIV-induced AIDS
in humans, SIV-induced AIDS in macaques is associated with
higher virus loads, a more rapid decline in immune function and
shorter survival (Mellors et al., 1996; Staprans et al., 1999;
Watson et al., 1997; Fuller et al., 2006). To accommodate thesedifferences, treatment was initiated at 14 days postinfection, a
time that is earlier than what is normally feasible in humans, so
that we could observe the effects of drug therapy on an albeit
crippled, but not yet completely ablated, immune response. We
reasoned that with respect to T cell immunity, the outcome of
such studies should parallel the effects of initiating HAART in
humans during later stages of infection. Furthermore, although a
cocktail of drugs is clearly more effective in reducing the virus
burden in HIV+ patients, a single drug regimen was employed
for this experiment because we wanted to evaluate viral rebound
once drug was discontinued and a drug cocktail administered
during acute infection with SIVmac251 had been previously
shown to suppress this event (Hel et al., 2000). Treatment was
continued for a period of 28 weeks at which time it was
discontinued. The remaining 4 animals served as untreated
infected controls.
Clinical disease course
The disease course in these animals is summarized in Table 1.
As expected, all four untreated infection controls died by
474 days pi with an AIDS-defining illness. Twenty-eight weeks
of PMPA therapy significantly prolonged survival in the treated
group (P=0.048, Mann–Whitney U, two-tailed) with only two
of these animals dying of AIDS within this timeframe. The six
surviving monkeys were sacrificed for tissue collection 589–
664 days pi.
Because recent reports had shown that lower viral loads and
disease resistance were associated with the Mamu-A*01 class I
allele in monkeys infected with SIVmac239 (Mothe et al., 2003;
Pal et al., 2002), the Mamu class I haplotype was determined for
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disease progression. Four of 8 of the monkeys in the PMPA-
treated group expressed the Mamu-A*01 class I allele (Table 1).
Among these animals, there was no apparent influence of this
allele on either survival or virus burden and drug responsiveness
(see below). This result is consistent with the observations of a
larger cohort of Mamu-A*01 positive animals infected with
SIV/DeltaB670 (Fuller et al., 2006) and suggests that the
Mamu-A*01 effect on disease may be dependent on the viral
isolate employed.
Virus burden
The virus burden in untreated infected controls was typical of
SIV/DeltaB670-infected rhesus macaques, with peak virus loads
of 106–108 RNA copies/ml by 14 days pi followed by a decline
to a setpoint by 4–8 weeks pi of 105–107 RNA copies/ml and a
plasma virus burden above 105 RNA copies/ml during chronic
infection (Fig. 1a). These levels are in contrast to that observed in
long-term nonprogressors (LTNP) infected with SIV/DeltaB670Fig. 1. Plasma virus load for infected untreated (a) and PMPA-treated animals (b, poo
are represented as progressors (grey lines) or long-term nonprogressors [LTNPs (black
(104 copies/ml). Animals were designated as treatment poor responders (b) or respo
below that of an LTNP. Plasma was serially sampled and virus copy number/ml plas
Boxed area represents treatment period (weeks 2–30 postinfection).where the virus burden during chronic infection remains at or
below 104 RNA copies/ml (Fig. 1a). Because LTNP typically
live for long periods in a clinically asymptomatic state, this value
was used as an efficacious endpoint for therapy.
The virologic response to PMPA varied significantly among
the animals, with half of the animals responding poorly to
treatment (poor responders: Fig. 1b) and half responding well
(responders: Fig. 1c). In poor responders, the virus burden
declined to one log or less than that observed in untreated
controls, with the virus load in one animal rebounding during
therapy. These values were not significantly different from that
in the untreated controls (P=0.39, Mann–Whitney U, two-
tailed). These results are in contrast to those obtained in the 4
responder monkeys where the virus loads were reduced to or
below the levels typically observed in LTNP monkeys
(responders; Fig. 1c). PMPA therapy in three of these animals
further reduced the virus burden below our detection limit, an
outcome we have not seen in untreated SIV/DeltaB670-infected
macaques (unpublished). These values were significantly lower
than those observed in untreated controls (P=0.029, Mann–r responders and c, responders) over time postinoculation. Untreated animals (a)
lines)]. The vertical line represents the average plasma virus burden from LTNPs
nders (c) based on maintenance of an average virus load during treatment to or
ma was calculated by real-time RT-PCR. Cutoff for the assay was 10 copies/ml.
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response to therapy has been observed in HIV-infected humans
(Grabar et al., 2000; Kaufmann et al., 1998), the differences
observed in our study were surprising given that the virus
inoculum and PMPA dose were the same, and the interval
between infection and initiation of therapy remained constant.
Discontinuation of PMPA treatment at 30 weeks p.i.
eventually resulted in viral rebound in all eight animals. The
post-therapy virus burden, however, differed between respon-
ders and poor responders, with the values at weeks 32 and 34
achieving statistical significance (P=0.03, Mann–Whitney U,
two-tailed). When compared to the values observed in untreated
controls, the virus burden in the poor responders was not
significantly different even though virus rebounded in three of
these animals soon after treatment interruption (Fig. 1b). These
results are in contrast to that observed in the PMPA responders
which remained below 105 in three animals for over a year after
treatment was withdrawn. Virus eventually rebounded in one
responder animal (M9799) 10 weeks after treatment interrup-
tion to a level achieved in untreated animals.
Evolution of PMPA resistance
In previous studies with PMPA-treated macaques infected
with SIVmac251, a lysine to arginine substitution at amino acid
65 was identified in the pol gene that conferred a 5-fold
resistance to PMPA in vitro (Van Rompay et al., 1996).
Additional mutations in RTwere also observed (N69S/T, I118V,
R82K, and R64K), but these were believed to be involved in
increasing viral fitness because these mutations were not
associated with increased drug resistance. The nucleotide
sequence of this region was therefore serially monitored in
this study in one untreated control (M10399), three poor
responders (M11399, M9699, and M12499), and the PMPA
responder animal (M9799) that rebounded above 105 copies/ml
to determine the relationship of drug responsiveness and PMPA
resistance (Fig. 2). With the exception of one clone, only the
wild type PMPA sensitive genotype was detected during acuteFig. 2. Number of clones expressing wild type or drug resistant reverse transcriptase (
from plasma viral cDNA at the indicated time postinoculation and sequenced. Bla
mutation, and grey bars represent RT with both K65R and the compensatory N69S/infection in any of the animals. During therapy, however,
resistance mutations readily dominated the infection of all three
poor responders. These changes included not only the K65R
primary resistance mutation, but also a N69S/T mutation (Van
Rompay et al., 1996). Interestingly, the K65 and N69S/T
mutations became fixed in the virus population in all three of
these animals, and remained as the dominant genotype
16 months after discontinuation of the drug. In contrast, these
mutations were only transiently detected in the responder
animal M9799. By 58 weeks pi, only the wild type sequence
could be detected even though the virus burden had rebounded
to the level achieved in untreated animals.
In vitro characterization of replication fitness of
SIV/DeltaB670 genotypes in human and macaque cells
Heteroduplex tracking analysis (HTA) was employed for
analysis of the viral quasispecies due to its proven utility in
epidemiologic studies to distinguish between multiple HIV
(Delwart et al., 1993, 1995) and SIV (Greenier et al., 2005;
Rybarczyk et al., 2004) genotypes, and the ease with which a
large number of samples can be analyzed. The V1–V2 region of
env served as the target for these assays because it is the most
hypervariable region of the genome (Overbaugh et al., 1991) and
thus should provide a sensitive indicator of viral evolution. The
SIV/DeltaB670 stock used for these experiments is comprised of
over 50 replication competent genotypes as defined by sequence
heterogeneity in V1–V2 (Amedee et al., 1995) (Fig. 3, lane 2),
with 2 genotypes, B670 clones 3 and 12, dominating (62 and
10%, respectively; Rychert et al., 2006). A single passage in
CEMX174 cells, a T cell line of human origin that is highly
permissive for replication of SIV, resulted in the selection of only
B670 clone 3 (Fig. 3, lane 3). In contrast, three successive
passages in rhesus primary PBMC resulted in the selective
outgrowth of only the B670 clone 12 genotype (Fig. 3, lane 1).
These results were confirmed by sequence analysis of over 30
cloned PCR fragments derived from a pool of multiple PCR
reactions of each sample (data not shown). As predicted from ourRT) from plasma virus. A portion of the reverse transcriptase gene was amplified
ck bars represent wild type RT, white bars represent RT containing the K65R
T mutation.
Fig. 3. HTA of V1-V2 region from: lane 1, viral cDNA from SIV/DeltaB670
passaged in primary rhesus PBMCs in vitro; lane 2, viral cDNA isolated and
amplified from an SIV/DeltaB670 inoculum; lane 3, viral cDNA from in vitro
passage in human T cell line (CEMx174); lane 4, probe alone; lane 5, V1-V2
amplified from plasmids containing the indicated clones and combined.
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of this stock in rhesus macaques clonally selected for B670 clone
12 (Holterman et al., 2001). Infection of macaques with
passaged virus was associated with higher virus loads, faster
disease progression, and shortened survival. Together, these data
demonstrate that propagation of SIV/DeltaB670 in human and
macaque cells is associated with selective, rapid outgrowth of
genotypes specific for each host. Loss of the B670 clone 3
genotype by passage in macaque cells or, conversely, selection
of this genotype by passage in human cells, provides a dramatic
display of the selective forces within each species that drive viral
divergence independent of immune selection.
Viral genetic evolution in vivo
The selection of specific genotypes made apparent by our in
vitro studies prompted us to evaluate the impact of PMPA
therapy on this process in vivo. Using the B670 clone 3 as the
probe, HTAwas performed on cDNA from longitudinal plasma
samples from all the animals in the study. In untreated
macaques, intravenous inoculation with the primary stock
resulted in variable patterns of expression of multiple genotypes
clearly discernable at 1 week pi, with either one or both of the
dominant variants (B670 clones 3 and 12), among others,
detected (Fig. 4). As expected from our in vitro experiments, by
30 weeks p.i, the B670 clone 3 genotype was lost in all of the
animals. By 10 weeks pi, changes in the quasispecies were
additionally visible in three of the animals, with the appearance
of new genotypes observed in some (M10399 and M10699,
Figs. 4c and b) and shifts in the dominant genotype observed in
others (M11599 and M4599, Figs. 4a and d). As time
progressed, the quasispecies became more complex, with
multiple new genotypes expressed at the terminal stages of
the disease. The one exception to this pattern was M11599 (Fig.
4a) where the loss of B670 clone 3 was the only major change
observed. This observation was not unexpected given that this
animal exhibited a “crash and burn” phenotype characterized bya high persistent virus burden, rapid disease progression, and
shortened survival (Zhang et al., 1988). Animals exhibiting this
phenotype fail to mount an immune response to SIV and are
thus presumably unable to drive evolution by immune selection.
Phylogenetic analysis of V1 sequences obtained over time in
representative animals confirmed that the emergence of new
genotypes revealed by HTAwas indeed in part due to evolution
of the input virus (data not shown).
Macaques that responded poorly to PMPA (Fig. 5) showed a
pattern similar to that observed in untreated animals. Multiple
genotypes were detected during acute infection, and an increase
in the complexity of the quasispecies occurred as the disease
progressed. This was particularly evident after the discontinua-
tion of PMPA. Loss of the B670 clone 3 genotype was also
apparent. It is interesting to note that in two of these animals a
major shift in the dominant genotype present in plasma was
observed 24 weeks pi (monkeys 9699 and 11399, panels b and
c, respectively). Like that seen in HIV-infected humans, these
data are consistent with the presence of a cellular or organ
reservoir that served as a source for this genotype. However, the
changes observed did not appear to be associated with either the
emergence of PMPA resistance or the discontinuation of therapy
because resistant genotypes had emerged before this time
(Fig. 2) and treatment was not terminated until 30 weeks pi.
Monkeys that responded to PMPA exhibited notable
differences when compared to poor responders or untreated
controls (Fig. 6). First, in three of these animals (M13799,
M9799, and M9099; Figs. 6b, c, and d, respectively) the quasi-
species appeared to be less complex. Second, as would be
expected by the significant reduction in virus burden associated
with effective antiretroviral therapy, virus evolution appeared to
progress more slowly as evidenced by continued expression of a
relatively unchanged quasispecies. The most striking example
of a slowing in virus evolution was the persistence of the B670
clone 3 genotype in two of the animals (monkeys 9799 and
9099; Figs. 6c and d, respectively). The limited template copy
number of some of the samples analyzed does not fully explain
this result because one monkey clonally infected with the B670
clone 3 genotype (M9799) rebounded to 106 copies/ml without
a visible change in the HTA. These data demonstrate that not
only did effective therapy apparently slow immune escape, it
also affected viral adaptation by preventing the loss of a
genotype that was poorly fit for replication in macaques. These
findings are of particular interest because they suggest that virus
can be more easily contained by adjunctive immunotherapy in
individuals who respond well to antiretroviral therapy.
N- and O-linked V1–V2 glycosylation sites during
infection/therapy
The acquisition of potential N-linked glycosylation sites in
the V1–V2 regions of both HIV-1 and SIV during the course of
disease progression has been implicated in the evasion of
neutralizing antibody (Chackerian et al., 1997; Koch et al.,
2003; Wei et al., 2003). We therefore evaluated the V1-V2
sequences identified in plasma over time in 2 untreated controls
(M10699 and M4599), two poor responders (M11399 and
Fig. 4. HTA of plasma virus cDNA derived V1–V2 envelope region sequences from SIV/DeltaB670-infected, untreated macaques. Numbers along the bottom indicate
week postinoculation. The last week is the necropsy sample. The V1–V2 envelope region was amplified by nested PCR. The resulting amplicons were hybridized to a
SIV/DeltaB670 clone 3 V1-V2 radiolabeled probe as described to track changes in this region. The asterisk and double asterisk indicate single strand probe and
homoduplex positions respectively. The top two bands in each lane are PCR remnants and are not included in the enumeration of variants. (a) M11599; (b) M10699; (c)
M10399; (d) M4599.
121R. Taber et al. / Virology 354 (2006) 116–131M12499) and the PMPA responder that rebounded after therapy
(M9799) to determine the impact of infection and therapy on
glycosylation of the SIV/DeltaB670 env (Fig. 7). Two potential
N-linked glycosylation sites were identified in the V2 region of
SIV/DeltaB670; both of these sites were completely conserved
among all animals and timepoints analyzed (data not shown).
Three conserved N-linked glycosylation sites and a variable
fourth site at position 14 were also identified in V1 (position 6
in Fig. 7). A comparison of samples from early vs. late time
points in untreated and poor responders failed to reveal a
consistent pattern of change affecting glycosylation at this
position. As expected, fewer changes in position 14 wereobserved in the responder monkey M9799. However, unlike
that seen in the other animals, genotypes at some of the last time
points analyzed had lost the last potential glycosylation site in
V1. Although the significance of this observation is unknown at
present, it is intriguing to speculate that this change may be
critical to the increase in virus burden observed in this animal,
either by providing antibody escape or enhancing fitness. It is
notable that, although a direct relationship between function and
O-linked glycosylation has not been shown, the hypervariability
found in the V1 region identified during infection and disease
progression also had a major impact on O-linked glycosylation
residues.
Fig. 5. HTA of plasma virus cDNA derived V1–V2 envelope region sequences from SIV/DeltaB670-infected, PMPA-treated poor drug responder macaques. Numbers
along the bottom indicate week postinoculation. Daily PMPA treatment was initiated 2 weeks pi and continued for 28 weeks. Boxed area represents samples collected
during therapy. The last week is the necropsy sample. The asterisk and double asterisk indicate single strand probe and homoduplex positions respectively. The top two
bands in each lane are PCR remnants and are not included in the enumeration of variants. (a) M10899; (b) M9699; (c) M11399; (d) M12499.
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To determine the association of virus evolution to SIV-
specific Tcell responses, the magnitude and breadth of the CD4+
andCD8+ Tcell responses were monitored over the course of the
study by T cell proliferation and gamma interferon ELISPOT,
respectively (Fig. 8). As expected, virus-specific CD4 and CD8
responses were undetectable in the “crash and burn” animal
M11599 throughout infection. The ability to mount a T cell
response during therapy varied widely among the other animals
in the study. After treatment interruption, CD8+ Tcell responses
increased significantly in PMPA responders, a finding that
confirms the maintenance of T cell memory responses in this
group. Predictably, the poorest CD8+ response was observed in
the responder animal infected with the most complex quasi-species (M10999). The differences in the magnitude of the Tcell
responses observed were not associated with a consistent change
in the viral quasispecies, however.
Analysis of the breadth of the CD8+ T cell responses was
further evaluated in the four Mamu-A*01 animals (2 poor
responders and 2 responders; Fig. 9). Although both poor
responders and responders recognized little more than the
immunodominant CM9 epitope (Allen et al., 1998) during
therapy, the repertoire of recognized epitopes increased in the
two Mamu-A*01 drug responders after treatment interruption.
In one of these animals (M13799), the increase in the breadth of
epitope recognition was associated with an increase in the viral
quasispecies complexity. However, in the second animal
(M9099), a shift in epitope recognition occurred without a
detectable change in the quasispecies.
Fig. 6. HTA of plasma virus cDNA derived V1-V2 envelope region sequences from SIV/DeltaB670-infected, PMPA-treated responder macaques. Boxed area
represents samples collected during therapy. Numbers along the bottom indicate week postinoculation. The last week is the necropsy sample for panels b, c, and d. The
necropsy sample for panel a is not shown, however, was indistinguishable from the week 83 sample. The asterisk and double asterisk indicate single strand probe and
homoduplex positions, respectively. The top two bands in each lane are PCR remnants and were not included in the enumeration of variants. (a) M10999; (b)
M113799; (c) M9799; (d) M9099.
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It was clear from these studies that SIV/DeltaB670-infected
monkeys differed with respect to their response to PMPA and,
not surprisingly, a robust response to PMPA correlated with
prolonged survival and maintenance of T cell function. Because
treatment was initiated during acute infection with the same
high dose stock in all of the animals, we sought to determinefactors that were present prior to treatment that may have played
a role in drug responsiveness. Although the parameters varied
among the animals, no difference in virus burden (Fig. 10a) or
magnitude of SIV-specific CD4+ (Fig. 10b) and CD8+ T cell
responses (Fig. 10c) that were present on the day therapy was
initiated (2 weeks postinfection) was identified. However, the
quasispecies expressed during the primary infection appeared
less complex in responders than that observed in the poor
Fig. 7. Amino acid sequence alignment of the envelope V1 region from untreated and PMPA-treated animals. The V1 region was amplified from viral cDNA at
indicated times postinoculation, cloned, sequenced, and aligned with the SIV/DeltaB670 clone 3 consensus (shown in bold). The animal number is preceded by an M,
week postexposure is indicated. Dashes indicate identity to clone 3 while dots indicate spaces inserted to aid in alignment. The number of identical clones is given at
the end of the sequence. Potential N-linked glycosylation sites are underlined, and acquired potential O-linked glycosylation sites are in bold. The loss of potential N-
linked glycosylation sites is indicated in lower case bold lettering (M9799).
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nously with the same stock (Fig. 10d). Although the difference
between the two groups fell short of statistical significance due
to the small number of animals in each group (P=0.057 Mann–
Whitney U, two-tailed), these results imply that the virologic
response to PMPA may be influenced by the degree of viral
complexity that existed prior to treatment.
Discussion
Virus evolution was examined in SIV/DeltaB670-infected
rhesus macaques undergoing antiretroviral therapy with PMPA.
We focused on the V1–V2 region of env for these studies
because it is the most hypervariable region in SIV (Overbaugh
et al., 1991) and has been highly informative in our hands inidentifying the phenotypic properties of specific genotypes
(Amedee et al., 1995; Trichel et al., 1997; Rychert et al., 2006).
Because all of the monkeys were inoculated intravenously with
the same well characterized virus stock (Amedee et al., 1995)
and received identical treatment, this study provided a unique
opportunity to characterize not only the virologic and
immunologic parameters associated with drug responsiveness,
it also enabled dissection of the impact of host adaptation and
immune escape on this process. The latter studies are important
because understanding how the virus responds to therapy at the
molecular level would greatly aid in the design of adjunctive
therapies that could enhance control of virus during treatment
and promote continued control once treatment is discontinued.
Host adaptation drives virus evolution independent of immune
pressures by selecting for genotypes with greater replication
Fig. 8. Postinfection SIV-specific lymphoproliferative (LPR) (a) and CD8+ T cell responses (b) in untreated naive macaques (top panels), PMPA poor responders
(middle panels), and PMPA responders (bottom panels). Shown are individual responses in each animal. SIV-specific LPR was measured following stimulation of
freshly isolated PBMC with whole Gag and Tat proteins. SIV-specific CD8+ T cell responses were measured by ELISPOT following stimulation of CD4+ T cell-
depleted PBMC with overlapping peptide pools encompassing SIV Gag and Tat and 8 representative CTL epitopes conserved in the challenge strain and frequently
recognized in Mamu-A*01 positive SIV-infected macaques (Allen et al., 2001).
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1999). Distinguishing between the two evolutionary pressures
should provide important insight in evaluating drug efficacy
because the ideal antiretroviral agent should not only reduce
virus burden and thereby reduce the rate of immune escape, but
also suppress the emergence of more virulent genotypes. In our
study, we were able to provide additional insight into host
adaptation by identifying genotypes in the SIV/DeltaB670
quasispecies selected for by passage in human vs. primate cells
in vitro. A single passage of the primary stock of SIV/
DeltaB670 in human cells resulted in a clonal infection with
B670 clone 3. Conversely, B670 clone 12 was selected for by
serial in vitro passage in monkey PBMC. Not surprisingly, a
common feature of the infection in untreated animals and poor
responders was the universal loss of the B670 clone 3 genotype.
Loss of this genotype as a result of poor replication fitness
represents a unique example of viral divergence associated with
adaptation to the host that is independent of immune escape.Monkeys were divided into drug responders (>1 log
reduction in virus burden) and poor responders (a reduction of
≤1 log) when compared to untreated infected controls. Serial
HTA of virion cDNA revealed significant changes in expression
of the SIV/DeltaB670 quasispecies associated with chronic
infection and treatment. Virus infection in poor responders
paralleled that of untreated controls, with the initial infection
characterized by expression of a complex quasispecies that
changed during disease progression. Virus evolution was
readily apparent by the appearance and disappearance of new
genotypes in both poor responders and untreated animals over
time. These findings were not surprising because they were
consistent with previous reports describing evolution driven by
escape from B and T cell immunity known to occur in both SIV
(Allen et al., 2000; Chackerian et al., 1997) and HIV (Koch
et al., 2003; Wei et al., 2003) hosts. What has not yet been
previously clear, however, is the contribution of host adap-
tation to this process.
Fig. 9. The breadth of the CD8+ T cell response in each Mamu-A*01 positive animal. Shown is the relative contribution of each of the 8 indicated Mamu-A*01-
restricted epitopes to the total response measured during the treatment period (weeks 2, 14), and after PMPA was withdrawn (weeks 32, 50, 79, 87).
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remained more constant over the course of infection and
treatment. These findings were most dramatically depicted in
the three monkeys whose virus loads were reduced below the
level of detection as a result of therapy. Importantly, not only
was the emergence of novel genotypes less frequent, but the
poorly fit “humanized” B670 clone 3 genotype remained as the
dominant genotype expressed in two of these animals until the
end of the study over a year after treatment was stopped.
Regardless of the response to therapy, viral rebound was
observed in all animals after treatment was stopped. Surpris-
ingly, this event was not associated with the emergence of novel
genotypes like that observed in some HIV+ patients during
treatment interruption (Chun et al., 2000; Dybul et al., 2003).
Cessation of HAART in these individuals, however, is usually
accompanied by the emergence of drug sensitive virus with
greater replication fitness than the drug-resistant predecessors.
In our studies, PMPA resistance mutants remained fixed in the
population in the poor responders, a condition that may not have
allowed a clear window with which to observe these effects.
Changes in the V1–V2 sequence were also analyzed to
determine whether the suppression in virus evolution observed
in the responders affected sequences associated with antibody
escape. V1–V2 sequence analysis reflected that observed by
HTA, with the responder animal showing little change in this
region during the course of the infection. Interestingly, the V1–
V2 evolution observed in the poor responders and untreated
controls did not consistently result in the acquisition of N-linked
glycosylation sites. Rather, similar to the observations of
Courgnaud et al. that revealed adaptation of sooty mangabey
propagated virus during passage in rhesus macaques, the V1
changes observed in our study appeared to have a greater impact
on O-linked glycosylation sequences associated with a hotspot
for insertions/deletions.The emergence of the K65R/N69S/T pol mutations
associated with PMPA resistance was also examined. No
difference was observed in the animals prior to the initiation
of therapy, with the circulating virus predominantly drug
sensitive in all of the animals. However, as expected for the
high rate of replication that persisted in the poor responders in
the face of therapy, resistant genotypes readily emerged
during treatment. Interestingly, these mutations became fixed
in the population in these animals and remained as the do-
minant genotype a year after treatment was interrupted. In
contrast, concordant with the slower rate of replication asso-
ciated with drug responsiveness, this genotype was slow to
emerge in the responder animal and was lost after treatment
was discontinued.
An examination of the impact of SIV-specific T cell
responses on virus evolution was also examined. No significant
difference in either the magnitude or the breadth of the T cell
response was observed in responders and poor responders
during therapy. However, a significant change in these
responses became apparent in the responders after treatment
was stopped. Interestingly, the increase in the breadth of the
epitope recognition observed in one of the animals was not
associated with a visible change in the viral quasispecies.
Although the V1–V2 region was not directly involved in the T
cell epitopes recognized in this animal, one would predict that
effective T cell-mediated control of replicating virus would
select for escape variants that would be identified by their own
V1–V2 sequence. These data suggest that changes in the
breadth of the T cell response do not always parallel that of virus
evolution and that accurate assessment of a functional role of T
cell immunity should include not only analysis of the T epitope
responses but analysis of the viral sequence encoding these
epitopes as well. Our findings are nevertheless consistent with
previous observations in that virologic control associated with
Fig. 10. Comparisons of SIV-specific lymphoproliferative responses (a), CD8+
T cell responses (b), plasma virus copy number (c), and the number of viral
variants (d) present prior to treatment. Individual values obtained at 2 weeks pi
for poor responders (left most bars) and responders (right most bars) are shown.
Statistical comparisons of the geometric mean values are reported in the figure
as the P value. Statistical analysis of the proliferative response was calculated
using 3 poor responders because results for M12499 were not available. The
number of viral variants discernable 2 weeks pi was determined visually.
Statistical analyses performed by Mann–Whitney U test, two-tailed analyses.
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virus-specific T cell response (George et al., 2005; Lifson et al.,
2000; Van Rompay et al., 2004). Further, effective therapy canhave a long-term impact on the maintenance of the host's T
cell immunity even after it is withdrawn, and support the
hypothesis that an effective means of immune evasion is rapid
evolution.
The dramatically different response to PMPA observed
among the animals prompted us to examine both immunolo-
gical and virological parameters that were present prior to the
initiation of therapy to identify factors that would be
predictive of treatment responsiveness. Clearly, this knowl-
edge would significantly aid in refining treatment of HIV-
infection in humans. Interestingly, there was no association
between PMPA responsiveness and either the peak virus loads
or the magnitude of the T cell response prior to therapy.
However, animals that responded well to therapy expressed a
less complex quasispecies during peak viremia than those who
did not. These findings are consistent with the recent
observation in HIV+ patients where it was determined that
expression of fewer genotypes during therapy correlated with
the ability to control rebound upon interruption of HAART
(Joos et al., 2005). Using the monkey model where infection
could be controlled, our data further suggest that a pattern of
less complexity before therapy may be predictive of
virological control during therapy. These results imply that
intrinsic factors such as innate immunity that exist in the host
at the time of the initial infection may play a role in restricting
initial infection with multiple genotypes and thereby enable
better T cell-mediated control by reducing the number of
target epitopes.
It is unlikely that the difference in drug responsiveness was
due to a difference in the proportion of drug resistant variants in
the animals that were below the level of detection because all of
the animals were inoculated intravenously with a high dose of
the same stock and exhibited indistinguishable peak virus loads.
Further, although it is possible that intrinsic host factors created a
selective barrier for the rare incoming drug-resistant variants, it
is more likely that the suppression of virus replication that
occurred after the establishment of the infection slowed the
generation of drug resistant strains. Regardless of the mechan-
ism, these results are encouraging because they support the
concept that therapeutic immunization may prove beneficial in
augmenting viral control in those individuals responsive to
therapy.
Materials and methods
Rhesus macaques
Macaques were maintained in accordance with the NIH
Guide to the Care and Use of Laboratory Animals under the
approval of the University of Pittsburgh Institutional Animal
Care and Use review committee. The University of Pittsburgh is
accredited by the American Association for the Accreditation of
Laboratory Animal Care International. These animals were part
of a larger cohort of animals used in a therapeutic vaccine trial
(Fuller et al., 2006). The Mamu class I haplotype was
determined by PCR-SSP and direct sequencing as previously
described (Knapp et al., 1997).
128 R. Taber et al. / Virology 354 (2006) 116–131Viral challenge
Macaques were fasted for 12 h, sedated with ketamine and
challenged intravenously with 1 ml of RPMI containing 10–100
TCID50 of cryopreserved SIV/DeltaB670. Clinical status was
monitored by complete blood cell counts and physical
examination consisting of palpation of peripheral lymph
nodes and spleen and monitoring for signs of opportunistic
infections. CD4+ T cell counts were measured by flow
cytometry after staining of whole blood as described (Martin
et al., 1993).
Antiretroviral therapy
Rhesus macaques received daily subcutaneous injections of
the antiretroviral (R)-9-(2-phosphonylmethoxypropyl)adenine
(PMPA) (Gilead Biosciences, Foster City, CA) at a dosage of
20 mg/kg starting 2 weeks after infection. Treatment was
continued without interruption for 28 weeks and then
discontinued to monitor the effects of therapy on viral rebound
and progression to disease.
In vitro propagation
The original stock of SIV/DeltaB670 consisted of the culture
supernatant derived from co-cultivation of a lymph node
homogenate from monkey B670 with rhesus monkey PHA
blasts (Murphey-Corb et al., 1986). Using this stock as the
starting material, a series of 3 serial passages was performed on
rhesus PHA blasts cultured in RPMI-1640 supplemented with
15% fetal calf serum and human recombinant IL-2. 100 TCID50
of the preceding culture supernatant harvested on days 10–14
postinfection was used as the source for the next round of
infection in each passage. On the final (4th) passage, the cells
were washed and resuspended in fresh medium on day 11
postinfection, and the supernatant harvested 3 days later for
genetic analysis.
Virus obtained from the second passage was used to
inoculate the monkeys in the study and for passage in
CEMX174 cells. One million CEMX174 cells were
inoculated with 100 TCID50 of the second passage and
the cells were subcultured every 3 days. The culture super-
natant used for genetic analysis was harvested 21 days
postinfection.
Reverse transcription
Synthesis of cDNA was performed in duplicate reactions
containing 5 MgCl, 1× PCR buffer II, 0.75 mM dGTP,
0.75 mM dATP, 0.75 mM dCTP, 0.75 mM dTTP, 1 U RNase
inhibitor, 1.2 U MULV reverse transcriptase (RT), and
2.5 μM random hexamers using 10% of the total viral
RNA obtained from high speed plasma pellets. Samples were
incubated at room temperature for 10 min, followed by 42 °C
for 12 min, and the reaction terminated by heating at 99 °C
for 5 min. Samples were cooled to 4 °C prior to PCR
amplification.Plasma viral loads
Virion-associated RNA in plasma was quantified by real-
time RT-PCR using 10% of total RNA in a Prism 7700 (Applied
Biosystems, Inc., Foster City, CA) using primers specific for the
viral long terminal repeat as described (Fuller et al., 2002). This
assay is linear over an 8-log range of template copy number and
has a sensitivity threshold of 10 copies/reaction. Control am-
plifications of samples omitting reverse transcriptase yielded
negative results. RNA copy numbers from the unknown plasma
samples were calculated from a similarly amplified external
standard and expressed as RNA copies/ml plasma.
V1–V2 env PCR amplification
The V1–V2 region of the envelope gene was amplified from
plasma derived cDNA to monitor viral evolution. Nested PCR
reactions were initiated immediately following completion of
the duplicate reverse transcription reactions. A 30 μl PCR
master mix containing 1× PCR buffer II, 2 mM MgCl2, 2.5 U
Amplitaq Gold (Perkin Elmer, Wellesley, MA), 200 mM
dNTPs, and 20 pmol each of the first round primers was
added directly to the reverse transcription reactions. The first
round primers were 5′-AGG-AAT-GCG-ACA-ATT-CCC-CT-
3′ (SIVmac239 nucleotides 6709 to 6728) and 5′-TCC-ATC-
ATC-CTT-GTG-CAT-GAA-3′ (nucleotides 7406 to 7385). The
amplifications were carried out in an Applied Biosystems Gene
Amp PCR System 9700 (Foster City, CA) by heating at 95 °C
for 10 min, followed by 27 cycles of 95 °C for 15 s, 55 °C for
15 s, and 72 °C for 30 s. The 100 μl second round reaction was
carried out with 2 μl of the first round reaction, 1× HotMaster
Taq Buffer with Mg2+, 200 mM dNTPs 20 pmol each second
round primer and 3 U HotMaster Taq DNA Polymerase
(Eppendorf, Hamburg, Germany). The amplification was
initiated by heating at 95 °C for 2 min and completed using
the first round cycling parameters. The second round primers
were 5′-CAG-TCA-CAG-AAC-AGG-CAA-TAG-A-3′ (SIV-
mac239 nucleotides 6845 to 6868) and 5′-TAA-GCA-AAG-
CATAAC-CT-GCG-GT-3′ (nucleotides 7305 to 7327). PCR
products from duplicate positive reactions were pooled and the
resulting 480-bp fragments were used in either the tracking
analysis or cloned for sequencing.
Pol PCR amplification and sequencing
Nucleotides 2985 to 3140 of the polymerase gene were
amplified from viral cDNA in duplicate nested PCR reactions as
previously described (Magierowska et al., 2004), with the
exception that HotMaster Taq DNA polymerase was used for
amplification (Eppendorf, Hamburg, Germany) using 10% of
total RNA. PCR resulted in a 156-bp fragment encoding RT
amino acids 52 to 90.
Heteroduplex tracking analysis
Nucleotide changes in the V1–V2 region of env were
monitored using a heteroduplex tracking analysis (HTA).
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the procedure originally described by Delwart and Gordon
(1997). The probe was generated in triplicate by amplifica-
tion of 1 ng of plasmid containing the SIV/DeltaB670 clone
3 surface glycoprotein using the second round primers and
cycling parameters used for V1–V2 (see above). The PCR
reactions were pooled, gel purified (QIAEX II gel
extraction kit, QIAgen, Valencia, CA), and eluted in
50 μl water. Amplification and gel purification were
repeated using 1 ng of the gel purified product as starting
material.
The radiolabeled probe was generated by asymmetric
amplification of 10 ng of the gel purified product in a 100 μl
reaction using only the second round forward primer. The
cycling conditions were: 1× PCR buffer II, 50 mM MgCl2
0.75 mM dCTP, 0.75 mM dTTP, 0.75 mM dGTP, 1:6 diluted
dATP, 10 μCi 32P dATP, 2.5 U Amplitaq gold. The resulting
radiolabeled single strand probe was subjected to electrophor-
esis at 60 mV for approximately 3 h, visualized by
autoradiography, excised, gel purified, and stored at −20 °C
until use.
Fifteen microliters of pooled V1–V2 PCR products was
individually mixed with 5 μl of a master mix containing 1 μl of
radiolabeled single strand probe, 2 μl HTA buffer (1 M NaCl,
100 mM Tris, pH 7.4, 20 mM EDTA), and 2 μl water. The
mixture was heated to 93 °C for 3 min and immediately placed
on ice. The duplexed DNA was subjected to electrophoresis in
5% MDE (Cambrex Bio Science, Rockland, ME) in 1× TBE
buffer (1 M NaCl2, 100 mM Tris pH 7.5, 20 mM EDTA) at
300 V for 3.5 h. The gel was dried and the bands were
visualized by autoradiography.
Sequence analysis
Duplicate PCR reactions were pooled and the resulting
fragments cloned into the pcDNA3.1/V5-HIS-TOPO TA
cloning vector (Invitrogen, Carlsbad, CA) for sequencing. Five
to 20 clones were randomly selected and sequenced in an ABI
370 automated DNA sequencer (Applied Biosystems). Align-
ment of the sequences was performed using CLUSTAL X
(Thompson et al., 1997). Sequences were prepared for
publication using SeqPublish (Los Alamos National Laboratory,
http://hiv-web.lanl.gov/content/index).
Estimation of potential N-linked and O-linked glycosylation
sites
V1–V2 sequences were analyzed for potential N-linked
glycosylation sites by visual inspection for the sequence
motif NXT/S. Potential O-linked sites were determined using
the program NetOGlyc [available at http://www.cbs.dtu.dk/
services/ NetOGlyc-2.0/ (Hansen et al., 1998)]. All potential
O-linked sites with a G-score above 0.5 were included in the
analysis. No sites (S or T residues) were found to have a
prediction above 0.758. The potential glycosylation sites in
the inoculum were determined using the published sequences
for SIV/DeltaB670 (Amedee et al.)Proliferation assay
Virus-specific T cell proliferative responses following
stimulation with whole SIV gag (Trinity Biosciences, Frederick,
MD) and tat (kind gift, Dr. David Watkins, University of
Wisconsin) recombinant proteins were measured as previously
described (Fuller et al., 2006).
IFN-γ ELISPOT assay
SIV-specific CD8+ T cells secreting IFN-γ were enumerated
by ELISPOT following stimulation with a synthetic epitope
peptide (QCB, Hopkinton, MA) or Gag and Tat peptides pools
consisting of 15-mers overalapping by 11 amino acids (Chiron,
Emeryville, CA) as previously described (Fuller et al., 2006).
Statistical analysis
Data from the untreated, poor responders and responders
were compared by the Mann–Whitney U test. All P values
reported are two-sided. In all cases, P<0.05 was considered
significant.
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